GoodRx Holdings Inc (GDRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
$3.34-5.11%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Defend market position against new entrants like TrumpRx: qualitative: 2 competitive threats (TrumpRx, Mark Cuban) vs 'no material loss' target.
GoodRx helps people save on prescription drugs with steady revenue near $775 million in 2026. It has a strong profit margin and free cash flow yield of 11%. The company is growing recurring revenue and maintaining margins despite competition. Its valuation is cheap compared to peers with a PE of 9.2 versus 28.4.
New competitors like TrumpRx threaten GoodRx's market share and growth. Revenue growth is slow at about 2.6% expected next year. Management changes and legal issues raise risks. The stock is expensive relative to its growth and faces margin pressure.
The market prices GoodRx about 29% below our fair value near $4.29. Analysts expect modest 2.6% revenue growth. Our view aligns with this cautious outlook but sees upside if growth and margins improve.
Breaks if: Significant market share loss or pricing pressure from competitors within next 4 quarters
Breaks if: Additional key executive or board member departures within next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. GDRX is currently navigating a high-risk environment while aiming for growth in its Pharma Direct and subscription segments.
The market seems to have priced in a level of fragility, as GDRX is considered expensive compared to its peers. However, the expectations gap indicates that the market may not fully account for its recent strong performance.
Management is focused on sustaining growth and improving margins, with recent results showing strong segment growth despite a slight overall revenue decline. The company is on track to achieve its Adjusted EBITDA target for the year, which could support its fundamentals in the near term.
The thesis hinges on management's ability to maintain growth while managing margins, as well as external factors like sector performance and economic conditions. Key indicators include the performance of sector peers and any shifts in guidance from GDRX.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: FCF yield falls below 10% next 4 quarters
Continue focusing on scaling Pharma Direct and subscription revenue to drive durable growth and preserve margin strength.
Stated as a priority in 2 of last 2 quarters. Pharma Direct revenue grew 76% and subscription revenue grew 39% year-over-year in 2026-Q2, while total revenue slightly declined 1% to $200.4M. Adjusted EBITDA margin declined modestly from 34.2% to 31.8%. Management's focus on scaling these segments is delivering mixed results with strong segment growth but overall revenue slightly down and margin pressure.
“We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance.”
“Our results demonstrate that the strategy we laid out last quarter is working and that we are building a sustainable value proposition.”
Breaks if: revenue falls below $765 million in FY26
Continue focusing on scaling Pharma Direct and subscription revenue to drive durable growth and preserve margin strength.
Stated as a priority in 2 of last 2 quarters. Pharma Direct revenue grew 76% and subscription revenue grew 39% year-over-year in 2026-Q2, while total revenue slightly declined 1% to $200.4M. Adjusted EBITDA margin declined modestly from 34.2% to 31.8%. Management's focus on scaling these segments is delivering mixed results with strong segment growth but overall revenue slightly down and margin pressure.
“We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance.”
“Our results demonstrate that the strategy we laid out last quarter is working and that we are building a sustainable value proposition.”
Overall, GDRX's performance is mixed but shows potential for growth if management can execute effectively. Not investment advice.